Opthea Limited OPT
At closeApr 1, 2025, 4:00 PM EDT
- Market cap
- 571.73M
- Revenue (ttm)
- 261.86K
- EPS (ttm)
- -2.76
- Shares out
- 153.89M
- Forward P/E
- -1.95
- Volume
- 3.02K
- Avg volume
- 28.93K
- Open
- 3.41
- Previous close
- 3.41
- Day's range
- 3.41 – 3.41
- 52-week range
- 1.79 – 5.45
- Beta
- 1.54
- Analysts
- Strong Buy
- Price target
- 12.17 (+256.8%)
- Earnings date
- Aug 29, 2024
2Y -0.62 (-15.38%)
Key statistics
- Enterprise value
- 4.14B
- PEG ratio
- 0.00
- Price / sales
- 2183.37
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -68.30%
- Free cash flow
- -94.87M
- Total cash
- 172.47M
- Total debt
- 200.63M
- Return on equity
- 0.00%
- Short % of float
- 0.06%
- 50-day average
- 3.91
- 200-day average
- 3.26
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 12.17
- Target (high)
- 18.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 29, 2024
Expected Aug 29, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 29, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Sep 12, 2023 | Jun 1, 2023 | -1.28 | — | — | — |
| Aug 29, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 13, 2023 | Oppenheimer | main | Outperform | Outperform |
| Aug 1, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2023 | EF Hutton | reit | Buy | Buy |
| Apr 17, 2023 | EF Hutton | init | — | Buy |
| Mar 13, 2023 | Oppenheimer | main | — | Outperform |
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- opthea.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on OPT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Regal Partners Ltd. | 5.40% | 2,907,403 | 10.49M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 4.04% | 2,173,622 | 7.84M | Sep 29, 2024 |
| Millennium Management Llc | 0.13% | 67,392 | 243.18K | Sep 29, 2024 |
| Stratos Wealth Partners, Ltd. | 0.05% | 29,600 | 106.81K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.05% | 26,632 | 96.10K | Sep 29, 2024 |
| Twin Lakes Capital Management, LLC | 0.04% | 19,806 | 71.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| USAA Mutual Fund Tr-Science & Technology Fund | 0.46% | 247,678 | 893.75K | Jul 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,049 | 18.22K | Oct 30, 2024 |